dr. agarwal on the safety profile of olaparib in hrr gene-mutant mcrpc
Published 4 years ago • 167 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
1:27
dr. bryce on the fda approval of rucaparib in brca-mutant mcrpc
-
1:23
dr. saad on the safety profile of apalutamide in m0crpc
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
1:15
dr. robson on the toxicity profile of olaparib in breast cancer
-
1:50
dr. shore on the safety profiles of relugolix and leuprolide acetate in prostate cancer
-
1:46
dr. agarwal on the qol with apalutamide in metastatic castration-sensitive prostate cancer
-
2:00
dr. zakashansky on the benefit of maintenance olaparib in brca ovarian cancer
-
1:50
dr. agarwal on pfs2 data from the titan trial in mcspc
-
1:38
dr. morgan on olaparib for metastatic castration-resistant prostate cancer
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
0:59
the evolution of parp inhibitors in ovarian cancer
-
6:18
value of olaparib in brca-mutated advanced ovarian cancer
-
38:45
the profound trial - lynparza in hrrm mcrpc
-
10:34
solo1: maintenance olaparib in advanced brca ovarian cancer
-
2:12
dr. patel on an analysis of olaparib and cediranib for ovarian cancer
-
1:01
choosing the correct parp inhibitor for prostate cancer